Image Source : Indian Pharma Post
1. Strategic Expansion into Advanced Markets
Biocon Biologics has officially launched Nepexto, its etanercept biosimilar, in Australia, marking a key milestone in its global rollout strategy.
- Nepexto is indicated for autoimmune conditions including rheumatoid arthritis and psoriatic arthritis
- The launch follows successful integration of Viatris’ biosimilars business across 120 countries
2. Product Profile and Regulatory Backing
- Nepexto is a biosimilar to Enbrel, offering comparable efficacy and safety
- Approved by Australia’s Therapeutic Goods Administration (TGA) under ARTG ID 386938
- Available as a 50 mg/1 mL auto-injector formulation
3. Market Implications and Patient Access
- The Australian launch strengthens Biocon’s presence in the Asia-Pacific region
- Supports Biocon’s commitment to affordable biologics and broader patient access
- Part of a portfolio that includes biosimilars for insulin, oncology, and immunology
Sources: Biocon Press Releases, American Pharmaceutical Review, Therapeutic Goods Administration Australia, Larvol Delta, Biocon Biologics Australia Product Locator
Advertisement
Advertisement